PDUFA dates November 2022: FDA calendar and catalysts.
0 PDUFA dates fell in November 2022. The FDA calendar also recorded 25 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
PDUFA dates in November 2022
No PDUFA dates are disclosed for this period as of November 16, 2026.
Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months
November 2022: other FDA decisions and filings
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Nov 2022Month disclosed | reproxalap | ALDX | NDA/BLA submission | — | Completed | SEC 8-K Exhibit 99.1 |
| Nov 2022Month disclosed | neopeptides (EVX-01) | EVAX | NDA/BLA submission | with metastatic melanoma | Completed | SEC Form 10-K |
| Nov 2022Month disclosed | TZIELD® (teplizumab) | MGNX | FDA approval | — | Approved | SEC Form 10-K |
| Nov 2022Month disclosed | mirvetuximab | PMVP | FDA approval | — | Approved | SEC 8-K Exhibit 99.1 |
| November 4, 2022 | Rybrevant (amivantamab-vmjw) | JNJ | Label expansion | — | Approved | openFDA Drugs@FDA |
| November 8, 2022 | Libtayo (cemiplimab-rwlc) | REGN | Label expansion | — | Approved | openFDA Drugs@FDA |
| November 9, 2022 | Elfabrio (pegunigalsidase alfa) | PLX | NDA/BLA submission | — | Completed | SEC Form 10-Q |
| November 10, 2022 | Imfinzi® (durvalumab) | AZN | Label expansion | — | Approved | openFDA Drugs@FDA |
| November 10, 2022 | Imjudo (tremelimumab-actl) | AZN | FDA approval | — | Approved | openFDA Drugs@FDA |
| November 16, 2022 | Rezvoglar (insulin glargine-aglr) | LLY | FDA approval | — | Approved | openFDA Drugs@FDA |
| November 17, 2022 | Trulicity (dulaglutide) | LLY | Label expansion | — | Approved | openFDA Drugs@FDA |
| November 22, 2022 | Piqray (alpelisib) | NVS | Label expansion | — | Approved | openFDA Drugs@FDA |
| November 23, 2022 | — | EVAX | FDA approval | — | Approved | SEC Form 10-K |
| November 28, 2022 | Udenyca (pegfilgrastim-cbqv) | CHRS | Label expansion | — | Approved | openFDA Drugs@FDA |
| November 30, 2022 | Brexafemme (ibrexafungerp) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
November 2022: dated readouts
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Nov 2022Month disclosed | VIITAL | ABEO | Topline readout | — | Positive | SEC Form 10-K |
| Nov 2022Month disclosed | COMP360 | CMPS | Topline readout | — | Positive | SEC Form 10-K |
| Nov 2022Month disclosed | WAKIX® (pitolisant) | HRMY | Topline readout | — | Positive | SEC Form 10-K |
| Nov 2022Month disclosed | TAVALISSE (fostamatinib) | RIGL | Topline readout | — | Missed primary endpoint | SEC Form 10-Q |
November 2022: trial starts and primary completions
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Nov 2022Month disclosed | zipalertinib (CLN-081) | CGEM | Trial start | — | Completed | SEC Form 10-K |
| Nov 2022Month disclosed | itolizumab (EQ001) | EQ | Trial start | moderate to severe alopecia areata, or AA, in Australia and New Zealand | Completed | SEC Form 10-Q |
| Nov 2022Month disclosed | sevasemten (EDG-5506) | EWTX | Trial start | — | Completed | SEC Form 10-K |
| Nov 2022Month disclosed | JAKAFI (ruxolitinib) | INCY | Trial start | — | Completed | SEC Form 10-Q |
| Nov 2022Month disclosed | suvecaltamide (JZP385) | JAZZ | Trial start | Parkinson's disease tremor | Completed | SEC Form 10-K |
| Nov 2022Month disclosed | repibresib (VYN201) | YARW | Trial start | NSV in November 2022 | Completed | SEC Form 10-Q |
Questions
What PDUFA dates are in November 2022?
0 PDUFA dates fell in November 2022. The FDA calendar also recorded 25 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
Can these dates change?
Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.